Jun Lai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jun Lai has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Gregory M. Laird
Accelevir Diagnostics, Baltimore, USA
1 shared publication - Janet D. Siliciano
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publication - Jeffrey N. Martin
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
1 shared publication - Kristen D. Ritter
Accelevir Diagnostics, Baltimore, MD 21202, USA
1 shared publication - Michael J. Peluso
Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA
1 shared publication - Peter Bacchetti
Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94143-0560, USA
1 shared publication
Latest Publications
- Top Cited Papers
- 27 February 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (4)
Differential decay of intact and defective proviral DNA in HIV-1–infected individuals on suppressive antiretroviral therapy
BACKGROUND: The relative stabilities of the intact and defective HIV genomes over time during effective antiretroviral therapy (ART) have not been fully characterized. METHODS: We used the intact proviral DNA assay (IPDA) to estimate the rate of change of intact and defective proviruses in HIV-infected adults on ART. We used linear spline models with a knot at seven years and a random intercept and slope up to the knot. We estimated the influence of covariates on rates of change. RESULTS: We studied 81 individuals for a median of 7.3 (IQR 5.9-9.6) years. Intact genomes declined more rapidly from initial suppression through seven years (15.7% per year decline; 95% CI -22.8%, -8.0%) and more slowly after seven years (3.6% per year; 95% CI -8.1%, +1.1%). The estimated half-life of the reservoir was 4.0 years (95% CI 2.7-8.3) until year seven and 18.7 years (95% CI 8.2-infinite) thereafter. There was substantial variability between individuals in the rate of decline until year seven. Intact provirus declined more rapidly than defective provirus ( P < 0.001) and showed a faster decline in individuals with higher CD4 + T cell nadirs. CONCLUSION: The biology of the replication-competent (intact) reservoir differs from that of the replication-incompetent (non-intact) pool of proviruses. The IPDA will likely be informative when investigating the impact of interventions targeting the reservoir. FUNDING: Delaney AIDS Research Enterprise, UCSF/Gladstone Institute of Virology & Immunology CFAR, CFAR Network of Integrated Systems, amfAR Institute for HIV Cure Research, I4C and Beat-HIV Collaboratories, Howard Hughes Medical Institute, Gilead Sciences, Bill and Melinda Gates Foundation.
- 27 February 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (4)
Top Cited PapersDifferential decay of intact and defective proviral DNA in HIV-1–infected individuals on suppressive antiretroviral therapy
BACKGROUND: The relative stabilities of the intact and defective HIV genomes over time during effective antiretroviral therapy (ART) have not been fully characterized. METHODS: We used the intact proviral DNA assay (IPDA) to estimate the rate of change of intact and defective proviruses in HIV-infected adults on ART. We used linear spline models with a knot at seven years and a random intercept and slope up to the knot. We estimated the influence of covariates on rates of change. RESULTS: We studied 81 individuals for a median of 7.3 (IQR 5.9-9.6) years. Intact genomes declined more rapidly from initial suppression through seven years (15.7% per year decline; 95% CI -22.8%, -8.0%) and more slowly after seven years (3.6% per year; 95% CI -8.1%, +1.1%). The estimated half-life of the reservoir was 4.0 years (95% CI 2.7-8.3) until year seven and 18.7 years (95% CI 8.2-infinite) thereafter. There was substantial variability between individuals in the rate of decline until year seven. Intact provirus declined more rapidly than defective provirus ( P < 0.001) and showed a faster decline in individuals with higher CD4 + T cell nadirs. CONCLUSION: The biology of the replication-competent (intact) reservoir differs from that of the replication-incompetent (non-intact) pool of proviruses. The IPDA will likely be informative when investigating the impact of interventions targeting the reservoir. FUNDING: Delaney AIDS Research Enterprise, UCSF/Gladstone Institute of Virology & Immunology CFAR, CFAR Network of Integrated Systems, amfAR Institute for HIV Cure Research, I4C and Beat-HIV Collaboratories, Howard Hughes Medical Institute, Gilead Sciences, Bill and Melinda Gates Foundation.